November 24, 2016 - By Darrin Black · 0 Comments
The stock of Amedica Corporation (NASDAQ:AMDA) registered a decrease of 3.63% in short interest. AMDA’s total short interest was 1.58 million shares in November as published by FINRA. Its down 3.63% from 1.64M shares, reported previously. With 246,000 shares average volume, it will take short sellers 6 days to cover their AMDA’s short positions. The short interest to Amedica Corporation’s float is 7.22%. The stock decreased 3.40% or $0.025 on November 23, hitting $0.71. About 1.92 million shares traded hands or 147.14% up from the average. Amedica Corporation (NASDAQ:AMDA) has declined 58.72% since April 22, 2016 and is downtrending. It has underperformed by 64.13% the S&P500.
Amedica Corporation is a commercial biomaterial company. The company has a market cap of $13.12 million. The Firm is a vertically integrated silicon nitride orthopedic medical device manufacturer. It currently has negative earnings. It is focused on using its silicon nitride ceramic technology platform to develop, manufacture and sell a range of medical devices.
Out of 2 analysts covering Amedica (NASDAQ:AMDA), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Amedica has been the topic of 3 analyst reports since August 14, 2015 according to StockzIntelligence Inc. The rating was initiated by Maxim Group on Thursday, November 10 with “Buy”. The company was initiated on Tuesday, January 5 by Ladenburg Thalmann. The stock of Amedica Corporation (NASDAQ:AMDA) earned “Buy” rating by Needham on Friday, August 14.
Amedica Corporation, incorporated on December 10, 1996, is a commercial biomaterial company. The Firm is a vertically integrated silicon nitride orthopedic medical device manufacturer. It is focused on using its silicon nitride ceramic technology platform to develop, manufacture and sell a range of medical devices. The Firm markets spinal fusion products. It is also engaged in developing wear- and corrosion-resistant implant components for hip and knee arthroplasty. The Firm markets its Valeo family of silicon nitride interbody spinal fusion devices in the United States, Europe and Brazil for use in the cervical and thoracolumbar areas of the spine. In addition to its silicon nitride spinal fusion products, the Company markets a line of non-silicon nitride spinal surgery products, which allows the Company to provide surgeons and hospitals with a solution for spinal procedures.
More recent Amedica Corporation (NASDAQ:AMDA) news were published by: Globenewswire.com which released: “Amedica Enhances Valeo IIâ„¢ Product Family With the Addition of Its Second …” on January 25, 2016. Also Globenewswire.com published the news titled: “Amedica Submits 24-Month Clinical Data to FDA for Clearance of Composite …” on November 10, 2015. Streetinsider.com‘s news article titled: “Amedica (AMDA) Names New Sales and Marketing VP; Valeo C+CsC Premarket App Not …” with publication date: November 22, 2016 was also an interesting one.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Darrin Black